Tuarascálacha Rannán na Seirbhísí - St. James's Hospital

FoilseacháinJ Clin Oncol 2003; 21: 473-882D, Richardson D, Jones JL, O’Byrne KJ.Kockelbergh RC. Increased microvessel counts in thebaseline resected superficial bladder cancercorrelate with the subsequent development ofinvasive disease.Clin Cancer Res 2003; 9: 2583 - 2566.Goggard JC, Sutton CD, Furness P, O’Byrne KJMatrix metalloproteinases 2 and 9 (gelatinases Aand B) expression in malignant mesothelioma andbenign pleura.Br J Cancer 2003; 88: 1553 - 1559.Edwards JG, McLaren J, Jones JL, Waller DA, O’Byrne KJ.Reversibility of liver failure secondary to metastaticbreast cancer by vinorelbine and cisplatinchemotherapy.Cancer Chemother Pharmacol 2003; 52: 367 – 370.Sharma RA, Decatris MP, Santhanam S, Roy R, OsmanAE, Clarke CB, Khanna S, O’Byrne KJHassan J, Anderson H, Burt P, Stout R, Swindell R,Dowd I, Beresford C, Thatcher N. A randomised studyof gemcitabine with carboplatin (GC) versusmitomycin, vinblastine and cisplatin (MVP) ormitomycin, ifosfamide and cisplatin (MIC) as firstline chemotherapy in advanced non-small cell lungcancer.Cancer 2003; 98: 542 - 53.Danson S, Clemons M, Middleton M, O’Byrne KAngiogenesis and the immune response as targetsfor the prevention and treatment of colorectalcancer.Onc Reps 2003; 10: 1625 – 1631.Sharma RA, Dalgleish AG, O’Byrne KJ.Dynamic contrast enhanced magnetic resonanceimaging as a biomarker for the pharmacologicalresponse of PTK787/ZD222584, an inhibitor of thevascular endothelial growth factor receptor tyrosinekinases, in patients with advanced colorectal cancerand liver metastases: results from two phase Istudies.J Clin Oncol 2003; 21: 3955-3964.Morgan B, Thomas AL, Drevs J, Hennig J, Buchert M,Jivan A, Horsfield MA, Mross K, Ball HA, Lee L,Mietlowski W, Fuxuis S, Unger C, O'Byrne K, Henry A,Cherryman GR, Laurent D, Dugan M, Marme D, StewardWP.Tumour necrosis correlates with angiogenesis and isa predictor of poor prognostic factor in malignantmesothelioma.Chest 2003; 124: 1916 – 1923.Edwards JG, Swinson DEB, Jones JL, Waller DA, O’ByrneKJNovel Targeted Treatment in Non-Small Cell LungCancer.Lung Cancer: Current Medical Literature 2003; 3: 1-6.O’Byrne KJDoxorubicin in ovarian cancer: current status andfuture prospects.MIMS 2003O’Byrne KJ, Sundar SMolecular response to imatinib mesylate followingrelapse after allogeneic SCT for CML.Blood.101; 1200. 2003.McCann S., Gately K., Conneally E and Lawler M.Guidelines for the diagnosis and management ofacquired aplastic anaemia.British Journal of Haematology. 123, 782-801. 2003.Marsh JCW., Ball SE., Darbyshire P., Gordon-Smith EC.,Keidan AJ., Martin A., McCann SR., Mercieca., Oscier D.,Roques AWW., Yin JAL.Donor leukaemia: perhaps a more commonoccurrence than we thought!Bone marrow transplantation. 32: 455-457. 2003.McCann S and Wright E.Outcome of autologous transplantation for mantlecell lymphoma: a study by the European Blood andBone Marrow Transplant and Autologous Blood andMarrow Transplant Registries.Br J Haematol. 2003 Mar;120(5):793-800Vandenberghe E, Ruiz de Elvira C, Loberiza FR, Conde E,Lopez-Guillermo A, Gisselbrecht C, Guilhot F, Vose JM,van Biesen K, Rizzo JD, Weisenburger DD, Isaacson P,Horowitz MM, Goldstone AH, Lazarus HM, Schmitz N.The toxicity and efficacy of donor lymphocyteinfusions given after reduced-intensity conditioningallogeneic stem cell transplantation.Blood. 2002 Nov1;100(9):3108-14.Marks DI, Lush R, Cavenagh J, Milligan DW, Schey S,Parker A, Clark FJ, Hunt L, Yin J, Fuller S, VandenbergheE, Marsh J, Littlewood T, Smith GM, Culligan D, Hunter82 82